Epstein-Barr virus latent membrane protein 1 and 2-derived peptides presented on MHC class I (EBV LMP1/2-MHC I)

Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) and latent membrane protein 2 (LMP2) are key oncogenic proteins expressed during the Latency II phase of EBV infection, which is characteristic of malignancies such as nasopharyngeal carcinoma and Hodgkin lymphoma (Young and Rickinson, 2004). These proteins are processed into short peptide fragments and presented on the cell surface by Major Histocompatibility Complex (MHC) class I molecules, serving as critical targets for cytotoxic T lymphocytes (Bollard and Heslop, 2016). LMP1 acts as a functional mimic of the CD40 receptor, while LMP2 mimics the B-cell receptor, both of which drive cell survival and proliferation in infected cells (Thompson and Kurzrock, 2004). Therapeutic strategies targeting these peptide-MHC complexes include adoptive T-cell therapies like tabelecleucel, TCR-engineered T cells, and therapeutic vaccines (Prockop et al., 2020). Because these antigens are viral in origin and restricted to infected or transformed cells, they provide a high degree of specificity for immunotherapy, although their use is limited by the requirement for specific HLA matching between the therapy and the patient.

Other names

LMP1/2-HLA complexesEBV Latency II antigensLMP1 and LMP2 T-cell epitopes

T-cell receptor (TCR) mediated recognition of viral peptide-MHC complexes leading to cytotoxic T lymphocyte (CTL) activation and tumor cell lysis.